Cannabinoid receptors in GtoPdb v.2025.1
Cannabinoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Cannabinoid Receptors [127]) are activated by endogenous ligands that include N-arachidonoylethanolamine (anandamide), N-homo-γ-linolenoylethanolamine, N-docosatetra-7,10,13,16-enoylethanolamine and 2-arachidonoylglycerol. Potency determinations of endogenous agonists at these receptors are complicated by the possibility of differential susceptibility of endogenous ligands to enzymatic conversion [5].There are currently three licenced cannabinoid medicines each of which contains a compound that can activate CB1 and CB2 receptors [119]. Two of these medicines were developed to suppress nausea and vomiting produced by chemotherapy. These are nabilone (Cesamet®), a synthetic CB1/CB2 receptor agonist, and synthetic Δ9-tetrahydrocannabinol (Marinol®; dronabinol), which can also be used as an appetite stimulant. The third medicine, Sativex®, contains mainly Δ9-tetrahydrocannabinol and cannabidiol, both extracted from cannabis, and is used to treat multiple sclerosis and cancer pain.
Authors
- Tom I. Bonner
- Vincenzo Di Marzo (ORCID: https://orcid.org/0000-0002-1490-3070)
- Christian C. Felder (ORCID: https://orcid.org/0000-0003-1134-8881)
- Allyn C. Howlett (ORCID: https://orcid.org/0000-0002-2810-0164)
- Mary E. Abood (ORCID: https://orcid.org/0000-0002-1744-2820)
- Peter J. Greasley (ORCID: https://orcid.org/0000-0002-2529-4477)
- Ken Mackie (ORCID: https://orcid.org/0000-0001-8501-6199)
- George Kunos (ORCID: https://orcid.org/0000-0003-1788-4976)
- Roger G. Pertwee (ORCID: https://orcid.org/0000-0003-3227-2783)
- Maurice R. Elphick (ORCID: https://orcid.org/0000-0002-9169-0048)
- Francis Barth (ORCID: https://orcid.org/0000-0001-8482-6552)
- Raphael Mechoulam (ORCID: https://orcid.org/0000-0002-6122-5698)
- Ruth A. Ross
- William A. Devane
- Miles Herkenham (ORCID: https://orcid.org/0000-0003-2228-4238)
- Ben Cravatt
- Heather B. Bradshaw (ORCID: https://orcid.org/0000-0001-7983-5729)
- S P H Alexander (ORCID: https://orcid.org/0000-0003-4417-497X)
- Guy A. Cabral
- Pierre Casellas
Institutions
- Hebrew College (US)
- North Carolina Central University (US)
- Scripps Research Institute (US)
- National Institutes of Health (US)
- University of Nottingham (GB)
- Queen Mary University of London (GB)
- Eli Lilly (United States) (US)
- University of Toronto (CA)
- University of Aberdeen (GB)
- Université de Montpellier (FR)
- University of Washington (US)
- Temple College (US)
- AstraZeneca (Brazil) (BR)
- Sanofi (Turkey) (TR)
- Indiana University (US)
- Virginia Commonwealth University Medical Center (US)
- Temple University (US)
Publication Details
- Journal
- IUPHAR/BPS Guide to Pharmacology CITE
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2218/gtopdb/f13/2025.1
- Citations
- 1
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 1.39